FREQUENCY THERAPEUTICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • September 23rd, 2019 • Frequency Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of ______________, 20[__] between Frequency Therapeutics, Inc., a Delaware corporation (the “Company”), and [Name] (“Indemnitee”).
Frequency Therapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • September 23rd, 2019 • Frequency Therapeutics, Inc. • Pharmaceutical preparations • New York
Frequency Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [●] shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [●] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of the Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
EMPLOYMENT AGREEMENTEmployment Agreement • September 23rd, 2019 • Frequency Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is entered into as of September 19, 2019 by and between Frequency Therapeutics, Inc. (the “Company”), a Delaware corporation, and Carl LeBel (“Executive”) and will become effective, if at all, upon the date of closing of the Company’s initial public offering of stock pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
TECHNOLOGY INCUBATION PROGRAM (TIP) 5th AMENDED LEASE AGREEMENT5th Amended Lease Agreement • September 23rd, 2019 • Frequency Therapeutics, Inc. • Pharmaceutical preparations • Connecticut
This Lease is made and entered into by and between the UNIVERSITY OF CONNECTICUT (hereinafter “UNIVERSITY”), a constituent unit of the State of Connecticut System of Higher Education, acting herein by its Vice President for Research pursuant to the provisions of Conn. Gen. Stat. § 4b-38, as revised, and Frequency Therapeutic, Inc., (hereinafter “COMPANY”) organized and existing under the laws of the Commonwealth of Massachusetts and having its principal address of 300 Technology Square, 8th Floor, Cambridge, MA 01239, and acting herein by David Lucchino, its Chief executive Officer, duly authorized.
SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • September 23rd, 2019 • Frequency Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Second Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of September 20, 2019, by and between Frequency Therapeutics, Inc., a Delaware corporation (“Frequency” or the “Company”), and David Lucchino (“Mr. Lucchino” or the “Executive”) (each a “Party” and collectively, the “Parties”).
